The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials

Ling, Juan; Pan, Cheng; Ge, Long; Ding-hua, Zhang; Shi, Anchen; Tian, Jinhui; Chen, Yajing; Li, Xiuxia; Zhang, Jing‐Yun; Yang, Kehu

doi:10.1007/s00592-018-1222-z

Cited by 46 publications

(36 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of the RCTs SAVOR TIMI 53 ® (saxagliptin [56]), EX-AMINE ® (alogliptin [57]), TECOS ® (sitagliptin [58]), CARMELINA ® (linagliptin [59]) on the effect of DPP-4 inhibitors on cardiovascular and renal endpoints each show cardiovascular safety of the investigated DPP-4 inhibitor in their primary endpoints, which was also confirmed in extensive meta-analyses [60][61][62][63][64][65][66]. DPP-4 inhibitors are therefore effective antidiabetics with few side effects and can be used very well as mono-and combination therapy if contraindications to the use of metformin are present and there is a corresponding patient preference.…”

Section: German Diabetes Association: Clinical Practice Guidelinesmentioning

confidence: 60%

Therapy of Type 2 Diabetes

Landgraf

Aberle

Birkenfeld

et al. 2019

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

The practical recommendations of the German Diabetes Society/ Deutsche Diabetes Gesellschaft (DDG) together with the German Society for Internal Medicine/Deutschen Gesellschaft für Innere Medizin (DGIM) are based on the contents of the National Treatment Guideline (Nationale Versorgungsleitlinie NVL) "Therapy of Type 2 Diabetes" [1]. The modifications in therapy and their justifications made in the present DDG practical recommendations were updated on the basis of new randomized controlled trials (RCTs) and meta-analyses and were consented by the DDG and the DGIM. Definition of Type 2 DiabetesType 2 diabetes is a chronic, very heterogeneous, multi-factorial, progressive disease characterized by inherited and acquired insulin resistance and qualitative and quantitative insulin secretion disturbances.Influenceable and uninfluenceable risk factors for type 2 diabetes are listed in the "Risk factors for type 2 diabetes" infobox. Therapeutic goalsIn the present recommendations, target ranges are identified which -with varying levels of strengths of evidence -inform the physician and the patient on which target range/target value should be aimed for according to current medical knowledge based on evidence and consensus. The main objective remains to set individual therapy goals primarily together with the patient and possibly his or her relatives and agreeing them optimally in writing on a quarterly basis (e. g. in the Health Passport Diabetes). General and specific therapeutic goalsThe therapeutic goals of people with type 2 diabetes depend on patient preference, comorbidity, duration of the disease, age and life expectancy, quality of life, cultural conditions, psychosocial circumstances and possibilities as well as abilities of the persons S73This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.

show abstract

Section: German Diabetes Association: Clinical Practice Guidelinesmentioning

confidence: 60%

Therapy of Type 2 Diabetes

Landgraf

Aberle

Birkenfeld

et al. 2019

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

show abstract

“…A Bayesian network meta-analysis indicated that only linagliptin could significantly lower body mass index compared with other DPP-4 inhibitors or placebo, and no statistical significance on body weight control observed when DPP-4 inhibitors were compared with placebo. [ 33 ]…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes

Zhuang¹,

Song²,

Ying

et al. 2020

Medicine

View full text Add to dashboard Cite

show abstract

“…For example, the obinutuzumab for rituximabrefractory indolent non-Hodgkin lymphoma obtained a value of 0.45 in Italy [20]. Interestingly, even though comparative data in the net-meta analysis showed no signi cant differences between the drugs, value differences still existed [21][22][23][24][25]. Since the weights and scores generated by the committee would inevitably revolve around their own perceptions, experience, training and value judgments, it is critical to have a multi-disciplinary vision.…”

Section: Discussionmentioning

confidence: 99%

Impact on Decision Making Framework for Medicine Purchasing in Chinese Public Hospital Decision-making: Determining the Value of Five Dipeptidyl Peptidase 4 (DPP-4) inhibitors

Bao

Gao

Meng

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Medicine purchasing in Chinese public hospitals is decided by the hospital Pharmacy Management Committee (PMC), that is complex, subjective and requires efficient methods to ensure transparency and consistency for the factors being considered. This study aimed to use the Evidence and Value: Impact on Decision Making (EVIDEM) framework to assess medicine in these hospitals. In this study anti-diabetic drugs DPP-4 inhibitors, which work by inhibiting the activation of the Dipeptidyl Peptidase 4 (DPP-4) inhibitors, were appraised.Methods: Following EVIDEM methodology, we convened an appraisal group and asked each individual to express their perspectives by assigning weights to each criterion. A systematic literature search for information of each criterion of five DPP-4 inhibitors was completed. Then the appraisal group scored for each criterion of the five DPP-4 inhibitors. The estimated value of the five DPP-4 inhibitors was obtained by Multi-Criteria Decision Analysis (MCDA) which combined individual weighting of each criterion with individual scoring for each intervention in each criterion. Results: By assigning weights, the most important criterion was the quality of evidence (4.01±0.52), and that the comparative cost consequences-non-medical cost had lowest weight (2.87±1.03). Criteria included disease severity, size of the affected population, comparative effectiveness, type of therapeutic/preventive benefit and cost of intervention, all of which were assigned the same weight of 3.58. After MCDA, the overall value orders for each DPP-4 inhibitor included Sitagliptin (0.45), Linagliptin (0.44), Vildagliptin (0.43), Alogliptin (0.42) and Saxagliptin (0.40). Conclusions: Based on EVIDEM framework and MCDA, we found that overall value of five DPP-4 inhibitors was similar. it is feasible to use the EVIDEM framework and MCDA in purchasing medicine for Chinese public hospitals.

show abstract

The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials

Cited by 46 publications

References 78 publications

Therapy of Type 2 Diabetes

Therapy of Type 2 Diabetes

Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes

Impact on Decision Making Framework for Medicine Purchasing in Chinese Public Hospital Decision-making: Determining the Value of Five Dipeptidyl Peptidase 4 (DPP-4) inhibitors

Contact Info

Product

Resources

About